Loading...
Market
Average survival extension reported for KIMMTRAK patients by NHS by end of 2025?
2
Resolution / Starting Odds
Less than 3 months • 25%
3 to 6 months • 25%
6 to 9 months • 25%
More than 9 months • 25%
NHS official reports or peer-reviewed medical journals
Story
NHS Offers KIMMTRAK to HLA-A*02:01-Positive Adults with Previously Untreatable Uveal Melanoma
Dec 3, 2024, 07:10 AM
A significant advancement in cancer treatment has been announced in England, with hundreds of patients diagnosed with unresectable or metastatic uveal melanoma set to receive access to KIMMTRAK, a pioneering drug developed by Immunocore. The National Health Service (NHS) confirmed that this reimbursement agreement will allow HLA-A*02:01-positive adults to access the treatment, which is expected to extend their lives by several months. This breakthrough, described as a 'game changer,' was developed by a research team in Oxford and marks a major milestone for patients suffering from this rare and previously untreatable form of eye cancer.
View original story
Similar markets
Less than 50 months • 25%
50-60 months • 25%
60-70 months • 25%
More than 70 months • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-10% • 25%
11-20% • 25%
21-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 1 month • 25%
1 to 6 months • 25%
6 to 12 months • 25%
More than 12 months • 25%
Less than 50% • 25%
50-60% • 25%
60-70% • 25%
More than 70% • 25%
Yes • 50%
No • 50%
0%-10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
PFS < 6 months • 25%
PFS 6-8 months • 25%
PFS 8-10 months • 25%
PFS > 10 months • 25%
Less than 50% • 25%
50% to 75% • 25%
76% to 90% • 25%
More than 90% • 25%